
|Videos|July 1, 2020 (Updated: July 22, 2020)
Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors
Author(s)Targeted Oncology
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Related Content
Advertisement





Encorafenib Combo Boosts PFS in BRAF V600E+ Metastatic Colorectal Cancer
Published: | Updated:



























